AR085132A1 - Composiciones farmaceuticas para el tratamiento de glioma maligno - Google Patents
Composiciones farmaceuticas para el tratamiento de glioma malignoInfo
- Publication number
- AR085132A1 AR085132A1 ARP120100357A ARP120100357A AR085132A1 AR 085132 A1 AR085132 A1 AR 085132A1 AR P120100357 A ARP120100357 A AR P120100357A AR P120100357 A ARP120100357 A AR P120100357A AR 085132 A1 AR085132 A1 AR 085132A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- glioma
- maligno
- pharmaceutical compositions
- pharmaceutically acceptable
- Prior art date
Links
- 206010018338 Glioma Diseases 0.000 title abstract 2
- 208000032612 Glial tumor Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 229940121849 Mitotic inhibitor Drugs 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical group O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000029824 high grade glioma Diseases 0.000 abstract 1
- 201000011614 malignant glioma Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2011050494 | 2011-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085132A1 true AR085132A1 (es) | 2013-09-11 |
Family
ID=45787254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100357A AR085132A1 (es) | 2011-02-04 | 2012-02-03 | Composiciones farmaceuticas para el tratamiento de glioma maligno |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130310407A1 (enExample) |
| EP (2) | EP2965757A1 (enExample) |
| JP (2) | JP5642892B2 (enExample) |
| KR (1) | KR101563069B1 (enExample) |
| CN (1) | CN103327975A (enExample) |
| AR (1) | AR085132A1 (enExample) |
| AU (1) | AU2012213036A1 (enExample) |
| BR (1) | BR112013019680A2 (enExample) |
| CA (1) | CA2823994A1 (enExample) |
| CL (1) | CL2013002193A1 (enExample) |
| CO (1) | CO6761366A2 (enExample) |
| EA (1) | EA201391131A1 (enExample) |
| IL (1) | IL227747A0 (enExample) |
| MA (1) | MA34952B1 (enExample) |
| MX (1) | MX2013008798A (enExample) |
| PH (1) | PH12013501461A1 (enExample) |
| SG (1) | SG192600A1 (enExample) |
| TN (1) | TN2013000333A1 (enExample) |
| TW (1) | TW201309298A (enExample) |
| WO (1) | WO2012104822A1 (enExample) |
| ZA (1) | ZA201306613B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2393117T3 (es) | 2005-09-12 | 2012-12-18 | Actelion Pharmaceuticals Ltd. | Composición farmacéutica estable que comprende una pirimidina-sulfamida |
| AU2010282744B2 (en) | 2009-08-10 | 2014-08-28 | Board Of Regents, The University Of Texas System | Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent |
| CN103397308A (zh) * | 2013-08-01 | 2013-11-20 | 光垒光电科技（上海）有限公司 | 用于mocvd设备的喷淋头 |
| TWI559928B (en) * | 2014-08-20 | 2016-12-01 | Academia Sinica | Methods for enhancing permeability to blood-brain barrier and uses thereof |
| KR101701619B1 (ko) | 2015-06-26 | 2017-02-01 | 건양대학교산학협력단 | 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물 |
| KR102574253B1 (ko) | 2020-12-15 | 2023-09-07 | 주식회사 시선테라퓨틱스 | 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물 |
| CN115317604B (zh) * | 2022-08-11 | 2023-09-22 | 南京脑科医院 | 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1693372A1 (en) | 2000-12-18 | 2006-08-23 | Actelion Pharmaceuticals Ltd. | Novel Sulfamides and their use as endothelin receptor antagonists |
| ES2393117T3 (es) | 2005-09-12 | 2012-12-18 | Actelion Pharmaceuticals Ltd. | Composición farmacéutica estable que comprende una pirimidina-sulfamida |
| WO2008111092A1 (en) * | 2007-03-09 | 2008-09-18 | Fresenius Kabi Oncology Limited | Crystalline temozolomide monohydrate and process for preparation thereof |
| MX2010008994A (es) * | 2008-02-20 | 2010-09-07 | Actelion Pharmaceuticals Ltd | Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. |
| AU2010282744B2 (en) * | 2009-08-10 | 2014-08-28 | Board Of Regents, The University Of Texas System | Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent |
-
2012
- 2012-02-03 TW TW101103560A patent/TW201309298A/zh unknown
- 2012-02-03 JP JP2013552318A patent/JP5642892B2/ja not_active Expired - Fee Related
- 2012-02-03 WO PCT/IB2012/050513 patent/WO2012104822A1/en not_active Ceased
- 2012-02-03 AR ARP120100357A patent/AR085132A1/es unknown
- 2012-02-03 PH PH1/2013/501461A patent/PH12013501461A1/en unknown
- 2012-02-03 US US13/983,383 patent/US20130310407A1/en not_active Abandoned
- 2012-02-03 EA EA201391131A patent/EA201391131A1/ru unknown
- 2012-02-03 MX MX2013008798A patent/MX2013008798A/es active IP Right Grant
- 2012-02-03 AU AU2012213036A patent/AU2012213036A1/en not_active Abandoned
- 2012-02-03 EP EP15178064.0A patent/EP2965757A1/en not_active Withdrawn
- 2012-02-03 CA CA2823994A patent/CA2823994A1/en not_active Abandoned
- 2012-02-03 SG SG2013058979A patent/SG192600A1/en unknown
- 2012-02-03 CN CN2012800059659A patent/CN103327975A/zh active Pending
- 2012-02-03 EP EP12706925.0A patent/EP2670405B1/en not_active Not-in-force
- 2012-02-03 BR BR112013019680A patent/BR112013019680A2/pt not_active IP Right Cessation
- 2012-02-03 KR KR1020137023170A patent/KR101563069B1/ko not_active Expired - Fee Related
- 2012-02-03 MA MA36217A patent/MA34952B1/fr unknown
-
2013
- 2013-07-10 CO CO13163973A patent/CO6761366A2/es not_active Application Discontinuation
- 2013-07-31 CL CL2013002193A patent/CL2013002193A1/es unknown
- 2013-08-01 IL IL227747A patent/IL227747A0/en unknown
- 2013-08-01 TN TNP2013000333A patent/TN2013000333A1/fr unknown
- 2013-09-03 ZA ZA2013/06613A patent/ZA201306613B/en unknown
-
2014
- 2014-10-28 JP JP2014219218A patent/JP2015057409A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR101563069B1 (ko) | 2015-10-23 |
| PH12013501461A1 (en) | 2019-03-22 |
| EP2670405A1 (en) | 2013-12-11 |
| AU2012213036A1 (en) | 2013-09-19 |
| TN2013000333A1 (en) | 2015-01-20 |
| MA34952B1 (fr) | 2014-03-01 |
| JP2015057409A (ja) | 2015-03-26 |
| CA2823994A1 (en) | 2012-08-09 |
| MX2013008798A (es) | 2013-10-17 |
| CO6761366A2 (es) | 2013-09-30 |
| TW201309298A (zh) | 2013-03-01 |
| JP2014504636A (ja) | 2014-02-24 |
| KR20130118981A (ko) | 2013-10-30 |
| ZA201306613B (en) | 2015-04-29 |
| CN103327975A (zh) | 2013-09-25 |
| WO2012104822A1 (en) | 2012-08-09 |
| CL2013002193A1 (es) | 2014-05-09 |
| IL227747A0 (en) | 2013-09-30 |
| US20130310407A1 (en) | 2013-11-21 |
| BR112013019680A2 (pt) | 2016-10-11 |
| NZ615005A (en) | 2015-10-30 |
| JP5642892B2 (ja) | 2014-12-17 |
| EP2965757A1 (en) | 2016-01-13 |
| SG192600A1 (en) | 2013-09-30 |
| EA201391131A1 (ru) | 2013-12-30 |
| EP2670405B1 (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| AR100006A1 (es) | Derivados de tubulisina | |
| AR077629A1 (es) | Mimetico de smac | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| UY33984A (es) | Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| UY35211A (es) | Compuestos tricíclicos | |
| NZ716765A (en) | Pharmaceutical combinations for the treatment of cancer | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| MX2015007940A (es) | Compuestos tricíclicos como inhibidores de cftr. | |
| AR066778A1 (es) | Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab | |
| CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |